Kadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Results of Operations and Financial Condition
ITEM2.02
|
Results of Operations and Financial Condition. |
On May15, 2017, Kadmon Holdings, Inc. (the Company) issued a
press release announcing its financial and operational results
for the three months endedMarch 31, 2017. A copy of this press
release is furnished herewith as Exhibit 99.1 to this Current
Report.
The information in this Item 2.02, including Exhibit 99.1 hereto,
is being furnished and shall not be deemed to be filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of Section 18 of the Exchange Act. The information in
this Item 2.02 shall not be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, as amended, or into any filing or other document to the
Exchange Act, except as otherwise expressly stated in any such
filing.
|
ITEM9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release issued by Kadmon Holdings, Inc., dated May |
About Kadmon Holdings, Inc. (NYSE:KDMN)
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease. Kadmon Holdings, Inc. (NYSE:KDMN) Recent Trading Information
Kadmon Holdings, Inc. (NYSE:KDMN) closed its last trading session 00.00 at 2.65 with 259,133 shares trading hands.